| Long-Term Effects of COVID-19 | Lifetime | 209 | IQ 1 | 98.04 |
| COVID-19 Clinical Research Studies | Lifetime | 394 | IQ 1 | 98.39 |
| Chemotherapy-induced cardiotoxicity and mitigation | Lifetime | 235 | IQ 1 | 95.20 |
| COVID-19 Impact on Reproduction | Lifetime | 271 | IQ 1 | 94.39 |
| Drug-Induced Hepatotoxicity and Protection | Lifetime | 596 | IQ 3 | 96.02 |
| Neuroprotection in Stroke and Neurodegeneration | Lifetime | 755 | IQ 1 | 93.51 |
| Acute Kidney Injury Research | Lifetime | 663 | IQ 1 | 94.23 |
| Inflammasome and immune disorders | Lifetime | 962 | IQ 1 | 92.83 |
| GDF15 and Related Biomarkers | Lifetime | 194 | IQ 1 | 90.43 |
| Pharmacology and Obesity Treatment | Lifetime | 821 | IQ 1 | 92.11 |
| Nuclear Receptors and Signaling | Lifetime | 831 | IQ 1 | 90.41 |
| Ginkgo biloba and Cashew Applications | Lifetime | 345 | IQ 1 | 88.56 |
| Paraoxonase enzyme and polymorphisms | Lifetime | 410 | IQ 1 | 79.74 |
| Nephrotoxicity and Medicinal Plants | Lifetime | 751 | IQ 1 | 68.43 |
| Andrographolide Research and Applications | Lifetime | 404 | IQ 3 | 62.36 |
| COVID-19 Clinical Research Studies | 2021-2025 | 9 | IQ 1 | 99.89 |
| Long-Term Effects of COVID-19 | 2021-2025 | 10 | IQ 1 | 99.78 |
| Nuclear Receptors and Signaling | 2021-2025 | 2 | IQ 1 | 98.34 |
| Parkinson's Disease Mechanisms and Treatments | 2021-2025 | 28 | IQ 1 | 99.39 |
| Inflammasome and immune disorders | 2021-2025 | 19 | IQ 1 | 98.61 |
| Adipokines, Inflammation, and Metabolic Diseases | 2021-2025 | 20 | IQ 1 | 97.06 |
| Neuroprotection in Stroke and Neurodegeneration | 2021-2025 | 16 | IQ 1 | 95.66 |
| Autophagy in Disease and Therapy | 2021-2025 | 89 | IQ 1 | 96.07 |
| COVID-19 Impact on Reproduction | 2021-2025 | 90 | IQ 1 | 96.19 |
| Alzheimer's disease research and treatments | 2021-2025 | 192 | IQ 1 | 97.87 |
| SARS-CoV-2 and COVID-19 Research | 2021-2025 | 735 | IQ 1 | 97.13 |
| Neuroinflammation and Neurodegeneration Mechanisms | 2021-2025 | 244 | IQ 1 | 95.50 |
| Pharmacological Receptor Mechanisms and Effects | 2021-2025 | 17 | IQ 1 | 94.96 |
| Neuroscience and Neuropharmacology Research | 2021-2025 | 315 | IQ 1 | 94.53 |
| Tryptophan and brain disorders | 2021-2025 | 326 | IQ 2 | 93.74 |
| Adenosine and Purinergic Signaling | 2021-2025 | 65 | IQ 1 | 91.55 |
| Stress Responses and Cortisol | 2021-2025 | 239 | IQ 2 | 93.00 |
| Nerve injury and regeneration | 2021-2025 | 102 | IQ 1 | 91.62 |
| Drug-Induced Hepatotoxicity and Protection | 2021-2025 | 121 | IQ 2 | 92.34 |
| Erythrocyte Function and Pathophysiology | 2021-2025 | 111 | IQ 1 | 91.75 |
| Metabolism, Diabetes, and Cancer | 2021-2025 | 251 | IQ 1 | 92.54 |
| Cholinesterase and Neurodegenerative Diseases | 2021-2025 | 144 | IQ 1 | 91.07 |
| Vitamin C and Antioxidants Research | 2021-2025 | 63 | IQ 1 | 90.46 |
| Neurological Disease Mechanisms and Treatments | 2021-2025 | 221 | IQ 1 | 88.36 |
| GDF15 and Related Biomarkers | 2021-2025 | 66 | IQ 1 | 86.03 |
| Chemotherapy-induced cardiotoxicity and mitigation | 2021-2025 | 188 | IQ 1 | 89.00 |
| Neutrophil, Myeloperoxidase and Oxidative Mechanisms | 2021-2025 | 194 | IQ 1 | 87.36 |
| Renin-Angiotensin System Studies | 2021-2025 | 52 | IQ 1 | 86.77 |
| Heme Oxygenase-1 and Carbon Monoxide | 2021-2025 | 196 | IQ 1 | 83.18 |
| Andrographolide Research and Applications | 2021-2025 | 25 | IQ 1 | 77.42 |
| Kruppel-like factors research | 2021-2025 | 158 | IQ 1 | 80.49 |
| S100 Proteins and Annexins | 2021-2025 | 284 | IQ 1 | 77.83 |
| Medicinal Plants and Neuroprotection | 2021-2025 | 380 | IQ 4 | 80.46 |
| Protease and Inhibitor Mechanisms | 2021-2025 | 239 | IQ 1 | 79.98 |
| Natural Antidiabetic Agents Studies | 2021-2025 | 891 | IQ 8 | 78.74 |
| Fibroblast Growth Factor Research | 2021-2025 | 301 | IQ 1 | 75.92 |
| Blood properties and coagulation | 2021-2025 | 286 | IQ 1 | 77.76 |
| Vagus Nerve Stimulation Research | 2021-2025 | 293 | IQ 1 | 75.17 |
| Sirtuins and Resveratrol in Medicine | 2021-2025 | 377 | IQ 1 | 71.35 |
| Biochemical effects in animals | 2021-2025 | 780 | IQ 1 | 71.56 |
| Eicosanoids and Hypertension Pharmacology | 2021-2025 | 460 | IQ 1 | 68.55 |
| Neuropeptides and Animal Physiology | 2021-2025 | 945 | IQ 1 | 67.44 |
| Peroxisome Proliferator-Activated Receptors | 2021-2025 | 755 | IQ 3 | 62.63 |
| Berberine and alkaloids research | 2021-2025 | 473 | IQ 1 | 52.83 |
| Calcium signaling and nucleotide metabolism | 2021-2025 | 539 | IQ 3 | 49.53 |